Yorke Justin W. - 30 Jan 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Director
Signature
/s/ Justin W. Yorke by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
30 Jan 2024
Net transactions value
+$21,544
Form type
4
Filing time
31 Jan 2024, 16:34:20 UTC
Previous filing
28 Nov 2023
Next filing
18 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Purchase $21,544 +8,000 +34% $2.69 31,232 30 Jan 2024 By Richland Fund, LLC F1
holding PCSA Common Stock 3,737 30 Jan 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.